


ATAGI 2023 booster advice


For people who have completed a primary course¹



Notes

1. For most people, a primary vaccination course consists of 2 doses. A third primary dose is recommended for people aged 6 months or older with severe immunocompromise. See [considerations for special populations: people who are immunocompromised](#).
2. Includes those with a medical condition that increases the risk of severe COVID-19 illness (refer to [ATAGI clinical guidance](#)) or those with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from COVID-19.
3. For people aged 12 years and older, mRNA bivalent vaccines are preferred. For ages in which a bivalent mRNA vaccine is not approved (children aged 5 to 11 years), Pfizer (COMIRNATY) 5-11 years (orange cap) can be used.
4. Consider a 2023 booster dose based on an individual risk benefit assessment with their immunisation provider.

ATAGI primary course advice



Notes

1. Includes those with severe immunocompromise, disability, and those who have complex and/or multiple health conditions that increase the risk of severe COVID-19.
2. Severely immunocompromised children who receive the 3-dose primary schedule of the Pfizer (COMIRNATY) 6 months to 4 years (maroon cap) vaccine do not require a fourth primary dose.
3. For people aged 12 years and older, a bivalent mRNA COVID-19 vaccine is preferred over original (ancestral) vaccines for primary vaccination, see [ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older](#). There is currently no bivalent mRNA COVID-19 vaccine available for children aged 6 months - 11 years, and existing original (ancestral) vaccines should continue to be used for this age group.